- Home
- FLYE vs RDHL Comparison
FLYE vs RDHL Comparison
Compare FLYE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 3.8M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FLYE | RDHL |
|---|---|---|
| Price | $2.29 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 21.8K |
| Earning Date | 03-19-2026 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,427,163.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.71 |
| 52 Week High | $21.80 | $3.31 |
Technical Indicators
Market Signals| Indicator | FLYE | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 41.68 |
| Support Level | $1.74 | $0.80 |
| Resistance Level | $5.87 | $0.90 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 74.16 | 58.19 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.